Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiotensin II: multitasking in the brain.

Juan M Saavedra1, Julius Benicky, Jin Zhou

  • 1Section on Pharmacology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA. Saavedrj@mail.nih.gov

Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
|April 8, 2006
PubMed
Summary

Blocking angiotensin II type 1 (AT1) receptors with candesartan reduces brain ischemia and stress responses in rats. This suggests AT1 receptor antagonism may treat brain ischemia and mood disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Grayscale inversion radiographic view provided improved intra- and inter-observer reliabilities in measuring spinopelvic parameters in asymptomatic adult population.

BMC musculoskeletal disorders·2016
Same author

Genomic analyses identify agents regulating somatotroph and lactotroph functions.

Functional & integrative genomics·2016
Same author

Enhanced Procoagulant Activity on Blood Cells after Acute Ischemic Stroke.

Translational stroke research·2016
Same author

Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity.

Biochemical and biophysical research communications·2016
Same author

Integrating microRNA and mRNA expression profiles of acute promyelocytic leukemia cells to explore the occurrence mechanisms of differentiation syndrome.

Oncotarget·2016
Same author

Fumaric Acid Production from Alkali-Pretreated Corncob by Fed-Batch Simultaneous Saccharification and Fermentation Combined with Separated Hydrolysis and Fermentation at High Solids Loading.

Applied biochemistry and biotechnology·2016

Area of Science:

  • Neuroscience
  • Cardiovascular Science
  • Pharmacology

Background:

  • Angiotensin II (Ang II) influences brain functions, including cerebrovascular flow and stress response.
  • Type 1 (AT1) receptors in the brain are key mediators of Ang II's central effects.
  • Spontaneously hypertensive rats (SHRs) exhibit heightened AT1 receptor activity, leading to cerebrovascular issues and stress vulnerability.

Purpose of the Study:

  • To review literature on the central effects of Ang II and its AT1 receptors.
  • To evaluate the impact of AT1 receptor blockade (candesartan) on experimental brain ischemia, cerebrovascular remodeling, inflammation, and stress responses in SHRs.

Main Methods:

  • Literature review of studies using spontaneously hypertensive rats (SHRs).
  • Analysis of research on candesartan's effects on experimental ischemia, cerebrovascular changes, inflammation, and stress responses (isolation, cold-restraint).

Related Experiment Videos

Main Results:

  • Central AT1 receptor antagonism by candesartan reversed pathological cerebrovascular growth, inflammation, and ischemia vulnerability in SHRs.
  • Pretreatment with candesartan prevented hormonal, sympathoadrenal, and gastric ulcer responses to stress.
  • AT1 receptor blockade normalized cortical receptor alterations associated with isolation stress, suggesting an anxiolytic effect.

Conclusions:

  • Sustained reduction of Ang II signaling via AT1 receptor antagonism offers a potential preventive and therapeutic strategy for brain ischemia.
  • This approach may also be beneficial for managing stress-related and mood disorders.
  • Further preclinical and clinical studies are warranted to validate the efficacy of AT1 receptor antagonism.